Get Results, Every Time.

OmniSeq MSI NGS® is a focused, simple and cost-effective method for clinicians to accurately assess MSI status for their patients.

  • OmniSeq MSI NGS® delivers microsatellite instability results from tumor only FFPE samples.

  • Eliminate the hassle to acquire and track matched normal DNA from tissue or blood.

  • Use MSI by NGS to identify appropriate patients for KEYTRUDA®, regardless of histology.

Polymerase Chain Reaction

Next-Generation Sequencing

  • Get results every time. PCR requires normal tissue, NGS does not.1
  • NGS examines more markers than PCR and may increase the sensitivity of the test for non-CRC samples.2
  • Omniseq MSI NGS is cost equivalent to PCR, with similar turnaround times.

Immunohistochemistry Mismatch Repair
Molecular Methods (PCR or NGS)

  • Molecular MSI tests may deliver fewer false positives than IHC.3
  • IHC interpretation is qualitative and subject to variation from lab to lab.3
  • IHC+ / PCR- samples have lower response rates than MSI-H samples.4

Specimen Requirements

  1. Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Cancer Med. 2018 Mar;7(3):746-756
  2. Salipante SJ, Scroggins SM, Hampel HL, Turner EH, Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem. 2014; 60:1192–9
  3. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn. 2008;10:293–300
  4. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017 Sep;18(9):1182-1191